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= Abstract =The purpose of this study is to  evaluate the possibility of application 
of SRCA to previously frozen tumor tissue. Mouse sarcoma-180 and human squa- 
mous cell carcinoma of the uterine cervix were used as implanting tumor speci- 
mens. The fresh tumor specimens were frozen by rapid freezing method and 
stored in a liquid nitrogen tank. On the 7th day of freezing, the specimens were 
thawed and diced into 1 cubic millimeter pieces, and implanted beneath the sub- 
renal capsule of ICR mice. The average viabilities before freezing and after thaw- 
ing were 86.7% and 10.5% in mouse sarcoma-180 respectively. And those of 
human uterine cervix cancer were 73.3% and 9.5% respectively. The evaluability 
of implanted tumor was 83.3% on the 6th day and 73.7% on the 12th day in 
mouse sarcoma, and in human cervix cancer, 75.0% and 66.7% respectively. The 
growth of previously frozen implanted mouse sarcoma was significant, 2.1 times 
on the 6th day and 73.9 times on the 12th day in volume. In the case of cervix 
cancer, the previously frozen tumor implants also grew significantly, 1.7 times on 
the 6th day and 2.1 times on the 12th day in volume. In conclusion, this prelimi- 
nary laboratory study showed that SRCA could be applied to  frozen tumor tissue 
as  well as  to fresh tissue for chemosensitivity test. 
Key Words : Subrenal c.apsuIe tui7101. inlplui~t assay (SRCA), C h e m o s e t i i i  rest, Frozen runlor 
rissll~ 
phys~cian preferences, not on the responsive- 
INTRODUCTION ness of individual tumors to chemotherapeutic 
agents because of the lack of a suitable tumor 
Patients with advanced stage cancers are sensitivity test. Thus several chemosensitivlty 
frequently treated with chemotherapeutic tests have been tried to predict the chemosensi- 
agents. But the chemotherapeutic agents are tivity of malignant tumors. For example, the dou- 
chosen on the basis of the statistical evaluation ble-layer- soft-agar method was developed. This 
of clinical stud~es involving many patients and technique is now commonly referred to as the 
- -- -- - - - -- - "clonogenic assay". But this assay has several 
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methods of exposure, existence of nonstandard- 
ized criteria for in vitro sensitivity, and methods 
of colony counting. Fur-thermore, the in vitro tis- 
sue culture systems bypass the normal metabol- 
ic processing capacity of the animal and there- 
fore might be inaccurate in reflecting the respon- 
siveness of the whole animal to chemotherapeu- 
tic agents. Many tumors cannot grow easily in 
tissue culture and up to 75% of tumor specimens 
may be unevaluable due to insufficient growth of 
control cultures. 
So the subrenal capsule assay(SRCA) was 
adapted for "in vivo" chemosensitivity testing. 
Originally the subrenal capsule assay was per- 
formed with athymic mice to aid In new drug 
screening, but it has been modified to handle 
fresh human tumor specimens. This assay is a 
precise technique which makes it possible to 
quantify minute changes in the size of human 
tumor xenografts implanted into the sub-capsu- 
lar region of the kidney in normal immunocompe- 
tent mice. The subrenal capsule assay is reliable 
technique for predicting clinical response to 
chemotherapy. This assay is relatively simple to 
perform and results are available within a week, 
so the test is quick enough to benefit the patient. 
Also, the relation between the efficacy of cyto- 
static treatment and its toxicity may be evaluated 
in this test. In Korea, we have already performed 
many SRC assays for various gynecologic malig- 
nancies to evaluate the chemosensitivities, the 
toxicities and the histopathologic changes of the 
tumor implants. 
Unfortunately because fresh tumor tissue is 
required in SRCA, it has to be performed imme- 
diately after surgery or biopsy. Moreover when 
the tumor is recurrent and there is difficulty in 
resampling frest- tumor specimens or when the 
decision on the chemotherapy is delayed, it can 
not be performed due to the absence of original 
fresh tumor tissue. The purpose of this study is to 
evaluate the possibility of application of SRCA to 
previously frozen tumor tissue. 
MATERIAL AND METHODS 
Mice with sarcornatous ascites from the 
Biologic Science Department of Seoul National 
University were used as the sources of sarcoma- 
180 tissue. The ascites were tapped and cen- 
trifuged and the precipitates were injected into 
the subcutaneous space of ICR mice to form 
solid tumors. In the case of human squamous 
cell carcinoma of the uterine cervix, tumor speci- 
mens were obtained at the time of operation from 
patients, most of whorn had advanced malignan- 
cies arid were being treated in the Gynecologic 
Departrnent of Seoul National University Hospital 
from January 1990 to February 1990. Specimens 
fr01-n six mice and six patients were used respec-. 
tively. 
The obtained fresh tumor specimens were 
cleaned of blood, necrotic tissue and fat and 
sectioned into about 3 x 3 x 3 cubic millime- 
ter pieces and immediately placed into sterile 
cryotubes containing 7.5% of DMSO(dimethy1 
sulfoxide; Merck, Darmstadt, West Germany), 
40% FBS(feta1 bovine serum; GIBCO, Grand 
Island, USA) and MEM(minimum essential medi- 
um; lrvine Scientific, USA). The specimens in the 
cryotubes(NUNC, Roskilde, Denmark) were 
frozen at -20" C for 1 hour and at -70" C for 6 
hours and stored in a liquid nitrogen tank(-196" 
C; MVE, USA). On the 7th day of freezing, the 
specimens were thawed in a 37" C-water bath for 
5 minutes. 
Just before freezing and after thawing, a via- 
bility test of the tumor specimen was done with 
trypan blue. The thawed tumor tissue was diced 
into nearly I cubic millimeter pieces with No. 10 
blades. While preparing the fragments of the 
tumor, young female adult ICR mice weighing 
25-35 gm were anesthetized with intraperitoneal 
injections of 0.22 M chloral hydrate solution 
(Yakuri Pure Chemical Co., Osaka, Japan), and 
then shaved on the left dorsal area and num- 
bered. An 5-8 mm skin incision was made on the 
left dorsum and the left kidney was exteriorized. 
Then a small nick was made in the kidney cap- 
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sule with a No. 11 surgical blade. A piece of 
tumor fragment was inserted into the subcapsu- 
lar region using a 20-gauge needle with trocar. 
The implanted tumor fragrrient was rrieasured in 
two dimensions with ocular microunits (OMU; 10 
OMU = 1 .Omm) under a stereomicroscope 
(Nikon, Type 102). After measuring the size of 
the implant, the kidney was returned into the 
abdominal cavity arid the wound was closed 
using a stapler. Anir-nals were allowed to recover 
from surgery in a cage under a heat lamp. 
In the case of human uterine cervical 
cancer, the immumosuppressive agent ,  
cyclosporin-A(SIGMA Chemical Co., St.Louis, 
USA) was injected subcutaneously at a dose of 
30 mg/kg daily to suppress the immune reaction 
to the xenografts. 
The experimental mice were divided into 
four groups; the 6th day-group of mouse sarco- 
ma, the 12th day-group of mouse sarcoma, the 
6th day-group of cervix cancer and the 12th day- 
group of cervix cancer according to the day of 
evaluating tumor growth and the kind of tumor 
specimen. Each tumor specimen was implanted 
in 6 to 7 experimental mice per group, so in total 
146 SRCA were performed. The mice were sac- 
rificed by cervical dislocation on the 6th or 12th 
day according to the group. Then the tumor- 
bearing kidneys were exposed and the tumor 
implants measured once again in situ. The aver- 
age change in tumor size in width and length 
measurements was calculated for each animal. 
A theoretical volume of the tumor can be calcu- 
lated using the formula for the volume of an ellip- 
soid, (L x W*)/2. We compared the means of 
width and length of implants to evaluate growth 
of implants and the growth of implanted tumor 
was histologically confirmed by a pathologist 
under hematoxylin-eosin staining. 
The evaluable assays were confined to the 
cases where the mean of width and length of the 
implant had increased and the area of necrosis 
did not exceed 50 percent. Paired t-test was 
used for statistical analysis. 
RESULTS 
Average v iab i  l i t  ies before freezing and 
after thawing 
The average viabilities before freezing and 
after thawing were 86.7 k 9.0% (range;  
70-95%) and 10.5 +- 2.7% (range; 6-15%) in 
mouse sarcoma-180 respectively. And those of 
human uterine cervix cancer were 73.3 + 9.5% 
(range; 60-90%) and 9.5 f 2.4% (range; 
5- 12%) respectively(Tab1e 1 ) .  
Evaluabi l i t y  o f  implanted tumor 
The evaluability of implanted tumor was 83. 
3%(30/36) on the 6th day and 73.7% (28138) on 
the 12th day in mouse sarcoma-180, and in 
human uterine cervical cancer, 75.0%(27/36) and 
66.7%(24/36) respectively. The unevaluable 
implants included the missing ones(l1 implants) 
or those showing regression(26 implants)(Table 2). 
Growth  o f  implants 
The growth of previously frozen and thawed 
Table 1. Cell viabilities of tumor specimens before 
freezing and after thawing 
- - 
Before Freezing After Thawing 
- - - -- -- - -- 
Mouse sarcoma-1 80 86.7 t 9.0% 10.5 k 2.7% 
(70-95%) (6-1 5%) 
Uterine cervlx cancer 73 3 + 11 0% 9 5 f 2 4% 
(60-90%) (5-1 2%) 
- - - 
*Mean + Standard dev~at~on (Range) 
Table 2. Evaluabil~t~es of implants 
- - - -- - --- - - .- -- - - 
Day 6 Day 12 
-- - -A - - - -- - --
Mouse sarcoma-1 80 83 3%(30/36) 73 7%(28/38) 
Uterine cervlx cancer 75 0%(27/36) 66 7%(24/38) 
-- - - - - - - - - - - - 
*Unevaluable Missing or necrosis of ~mplants 
implants of mouse sarcoma-1 80 was significant. 
The increment in volume was 2.1 times on the 
6th day (from 10.2 k 1.2 OMU to 13.5 1 + 1 2 
OMU in mean of width and length) and 73.9 
times on the 12th day (from 10.6 k 1.2 OMU to 
45.5 -t 12.9 OMU in mean of width and length). 
In the case of uterine cervical cancer, the previ- 
ously frozen and thawed tumor implants also 
grew significantly, 1.7 times on the 6th day (from 
10.0 f 0.8 OMU to 11.9 k 0.9 OMU in mean of 
width and 1ength)and 2.1 times on the 12th day 
(from 10.2 + 0.6 OMU to 13.5 k 1.8 OMU in 
mean of width and length)(Table 3,4). 
D l  SCUSS l ON 
For over 10 years, many clinical investiga- 
tors have made considerable efforts to develop 
an in vivo test that could accurately predict the 
chemosensitivity of a malignant tumor such as 
microbial culture and sensitivity assays. A num- 
ber of assay techniques have evolved including 
"clonogenic assay". The preliminary clinical 
experience with the stem cell clonogenic assay 
was encouraging. The overall accuracy of the 
test was reported to be greater than 75% with 
Table 3. Cell v~ab i l~ t~es  of tumor specimens before freez~ng and after thawing 
- -- - -- - -- -- - -- -- - - - - 
ln~tial OMU F~nal OMU P-value Increment ~n volume 
-- - - - - -- -- -- - -- - - - 
Day 6 1 0 3 i 1 2  135f 1 2  <O 01 2 1 t~mes 
Day 12 10.6 + 1.2 
- -- - -- 
*Mean f Standard dev~at~on 
73.9 times 
-- 
Table 4. Growth of human uterlne cerv~cal cancer ~mplants 
- - -  - - - - - - - - - - - -- - -- - 
ln~ t~a l  OMU F~nal OMU P-value Increment ~n volume 
-- - - - -- - - - - - - - - - --- - - - -  - - - -  -- - - 
Day 6 1 0 3  + 0 8  1 1 9 + 0 9  <O 01 21 7 t~mes 
Day 12 10.2 + 0.2 
- - - - - 
*Mean f Standard deviation 
85-92% for the prediction of clinical resistance to 
chemotherapy. But the current problems in the 
assay methods include low plating efficiencies, 
nonstandardized drug concentrations and meth- 
ods of exposure, existence of nonstandardized 
criteria for in vitro sensitivity, and methods of 
colony counting. The major disadvantages of the 
clonogenic assay are the dismal cloning efficien- 
cy of about 0.001%, evaluable growth rates of 
23% to 36%, the high incidence of bacterial and 
fungal contamination, the long time necessary 
for evaluable clones to develop, and the techni- 
cal difficulties of obtaining a single cell suspen- 
sion. 
But there are several merits of the SRC 
assay. The use of fresh tumor fragments pro- 
vides well preserved tissue permeability barriers 
for chemotherapeutic drug testing. Also, drugs 
that need in vivo activation such as cyclophos- 
phamide are evaluable in this in vivo assay. 
Conceptually intact cell-to-cell contact and spa- 
tial relationships considered to be important in 
predicting true drug activity can be afforded by 
SRC assay. The SRC assay is technically simple 
and the results are available within a week allow- 
ing use of the results in the treatment of cancer 
patients. 
In our study, the viabilities of tumor tissue 
after thawing might have been dramatically 
improved if we had adopted procedures for sin- 
gle cell suspension before freezing. But as men- 
tioned earlier, procedures for single cell suspen- 
sion are technically difficult, need much time, are 
expensive and through these procedures tumor 
tissue may lose its own stromal microstructures. 
So we selected the method of direct freezing 
and thawing of intact tumor tissue. 
Tumors have the potential to grow in the 
subrenal capsule assay because of the rich 
blood supply to the subcapsular region. The 
small size of the tumor graft allows for diffusion 
of nutrients as well as test drugs into the implant 
without the lag time that would be required to 
develop a vascular supply. Many studies have 
shown that the increase in tumor size of untreat- 
ed tumors is related to the mitotic activity as well 
as to the degree of tumor necrosis present in the 
surgical specimen. Recent histologic studies by 
Reale et al. showed that (a) tumor histologic 
architecture is preserved in the implants up to 
day 6 in both immunocompetent and athymic 
nude mice; (b) host infiltrate of inflammatory 
cells begins as early as day 3 and peaks at day 
10; (c) the extent of infiltration does not signifi- 
cantly affect tumor size up to and through day 6. 
Levi et a/. (1  984) found that fresh implants of 
human tumor retain their proliferative and 
metabolic capacity at least 4 days after implan- 
tation in the renal capsule of immunocompetent 
mice. He also found that the mean tumor size 
from any tumor specimen did not differ between 
days 4 and 6. These observations suggest that 
the cellular infiltration is not artifactual to the 
extent that it precludes the validity of a simple 
tumor size parameter for evaluating drug effects. 
Furthermore, the immune system of the mice 
cannot reject the implant of the tumor within such 
a short 6-day time frame. 
But frozen and thawed tumor specimens in 
our study had only a small portion(approximate1y 
10%) of viable cells. So if we should perform the 
chemosensitivity test by injecting chemothera- 
peutic agents at the time of implantation, almost 
all viable tumor cells might be sacrificed and 
interpretation of SRCA be impossible. To solve 
this problem, we planned the assay to continue 
till the 12th day of implantation for sufficient 
growth of implants, and injection of the 
chemotherapeutic agent could be started from 
the 7th day of implantation. In other words, we 
tested the possibility of the growth of the frozen 
and thawed tumor tissues in subrenal capsular 
space in the 6-day groups and then in the con- 
trol groups of chemosensitivity by SRCA with 
those tissues in the 12-day groups. 
Hunter et a/. (1982) reported that an aver- 
age of 60% showed positive growth and 11 % 
demonstrated no measurable change in size of 
untreated tumors implanted. In our previous 
study, we obtained similiar positive growth(73. 
8%) and no measurable growth (14.1%). In the 
present study, the evaluabilities mean the pro- 
portions of positive growth as defined and 
ranged from 66.7% to 83.3%. This showed that 
the growth of frozen and thawed tissue was com- 
parable to that of fresh tissue. 
In the case of human uterine cervix cancer 
implants, immunocompetent ICR mice show infil- 
tration of inflammatory cells as an immune reac- 
tion to xenograft. This had not been a problem in 
4 -day or 6-day SRCA using fresh tumor tissue 
because the immune system of the mice cannot 
reject the implant of the tumor within such a 
short 6-day time frame. But in the present study, 
because we continued the assay till the 12th day 
of implantation, immunosuppression against 
xenograft rejection was required. Kusuyama et 
a/. reported succesful immunosuppression by 
alternate daily subcutaneous injection of bre- 
d~nin at a dose of 200mglKg or by daily subcuta- 
neous injection of cyclosporin-A at dose of 
6OmglKg. We obtained excellent immunosup- 
pression by daily subcutaneous injection of 
cyclosporin-A at a dose of 6Omg/Kg to the dorsa 
of the mice. 
We adopted the rapid-cooling freezing 
method of 1 hour-freezing at -20" C followed by 6 
hour-freezing at -70" C to simplify the procedure. 
However because it is known that slow-cooling 
freezing provides better viabilities of cells, more 
studies are required of the cooling rate in SRCA 
with frozen tissue. 
In the present study, we selected dimethyl 
sulfoxide as a cryoprotectant according to the 
method of Lovelock and Bishop, but other cry- 
oprotectants such as glycerol or propylene could 
be applied in further studies. 
In conclusion, this preliminary laboratory 
study showed that frozen and thawed tumor tis- 
sues could grow in subrenal capsular space till 
the 12th day of implantation and so SRCA could 
be applied to frozen tumor tissue as well as fresh 
tissue for chemosensitivity test. From now on, we 
can perform SRCA at anytime we need by freez- 
ing of the tumor tissue at the time of surgery or 
biopsy. 
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